Newland Pharmaceutical Co., Ltd. (SHE:301277)

Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	102.22	281.58	270.02	51.13	34.21	36.45
Trading Asset Securities	558.53	525.16	589.5	701.36	8.67	-
Cash & Short-Term Investments	660.76	806.75	859.52	752.49	42.88	36.45
Cash Growth	-17.35%	-6.14%	14.22%	1654.94%	17.63%	-34.12%
Accounts Receivable	309.35	332.61	240.9	360.46	269.6	179.29
Other Receivables	0.12	0.24	0.19	0.26	0.16	0.3
Receivables	309.47	332.85	241.09	360.72	269.76	179.6
Inventory	68.02	45.06	31	53.52	78.57	49.42
Prepaid Expenses	-	-	-	-	-	1.25
Other Current Assets	18.04	10.37	25.04	20.38	9.8	1.78
Total Current Assets	1,056	1,195	1,157	1,187	401	268.49
Property, Plant & Equipment	648.31	574.78	388.2	295.52	225.67	210.5
Other Intangible Assets	49.84	36.82	38.08	38.77	39.71	39.9
Long-Term Deferred Tax Assets	-	-	-	-	1.01	0.83
Long-Term Deferred Charges	2.27	3.38	5.61	1.29	-	-
Other Long-Term Assets	8.96	3.73	20.96	11.08	0.51	2.23
Total Assets	1,766	1,814	1,610	1,534	667.9	521.96
Accounts Payable	125.39	138.66	87.75	106.37	80.26	43.5
Accrued Expenses	18.46	23.78	30.33	18.18	27.81	23.56
Short-Term Debt	-	0.73	-	-	91.33	90.12
Current Portion of Long-Term Debt	-	-	-	-	4.66	-
Current Portion of Leases	2.76	-	1.99	2.84	-	-
Current Income Taxes Payable	-	-	-	-	3.05	4.26
Current Unearned Revenue	0.5	5.32	4.43	4.61	1.68	0.41
Other Current Liabilities	52.63	48.3	14.96	24.01	11.8	15.89
Total Current Liabilities	199.74	216.78	139.47	156.01	220.58	177.73
Long-Term Debt	-	-	-	-	30.39	20.02
Long-Term Leases	3.72	2.25	0.73	2.88	-	-
Long-Term Unearned Revenue	41.76	41.88	10.04	10.3	10.56	10.81
Long-Term Deferred Tax Liabilities	12.29	9.77	9.78	5.39	-	-
Total Liabilities	257.5	270.69	160.02	174.58	261.53	208.57
Common Stock	392.08	280.06	200.04	133.36	100	100
Additional Paid-In Capital	532.74	644.77	724.78	791.46	5.49	1.78
Retained Earnings	576.71	610.7	517.09	424.79	292.48	207.5
Comprehensive Income & Other	5.88	6.67	6.11	6.33	4.56	4.11
Total Common Equity	1,507	1,542	1,448	1,356	402.53	313.39
Minority Interest	0.76	0.85	1.47	3.25	3.85	-
Shareholders' Equity	1,508	1,543	1,449	1,359	406.38	313.39
Total Liabilities & Equity	1,766	1,814	1,610	1,534	667.9	521.96
Total Debt	6.48	2.98	2.72	5.72	126.38	110.14
Net Cash (Debt)	654.28	803.77	856.8	746.77	-83.5	-73.69
Net Cash Growth	-17.99%	-6.19%	14.73%	-	-	-
Net Cash Per Share	1.69	2.05	2.19	2.48	-0.28	-0.25
Filing Date Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Total Common Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Working Capital	856.55	978.24	1,017	1,031	180.43	90.76
Book Value Per Share	3.84	3.93	3.69	3.46	1.37	1.07
Tangible Book Value	1,458	1,505	1,410	1,317	362.82	273.49
Tangible Book Value Per Share	3.72	3.84	3.60	3.36	1.23	0.93
Buildings	362.95	211.94	169.21	151.69	148.36	128.24
Machinery	320.97	295.69	235.66	187.31	125.82	115.55
Construction In Progress	139.25	222.1	106.7	55.35	33.02	32.52

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.